Monte Rosa Therapeutics, Inc. GLUE
10.25 USD -0.26 (-2.43%)
Nov 11, 2026, 11:49 AM EST
10.19 Day range 10.55
9.68 52-week range 25.77
- YTD
- -34.66%
- 1 year
- -28.46%
News
benzinga.com Monte Rosa Therapeutics Presents Preclinical Data Of MRT-8102 At ACR Convergence 2026 Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the presentation of preclinical…
globenewswire.com Monte Rosa Therapeutics Presents Preclinical Data at ACR Convergence 2026 on the Potential of MRT-8102 in Gout NEK7-directed molecular glue degrader inhibited NLRP3 inflammasome activation in human experimental systems and demonstrated anti-inflammatory activity in a rabbit model of gouty arthritis GEMINI-1,…
benzinga.com Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $25 Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $27 to $25.
zacks.com Monte Rosa Therapeutics (GLUE) Tops Q3 Earnings and Revenue Estimates Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.03 per share, beating the Zacks Consensus Estimate of a loss of $0.1 per share. This compares to a loss of $0.33 per share a year…- benzinga.com Monte Rosa Therapeutics Q3 EPS $0.03 Beats $(0.29) Estimate, Sales $54.366M Beat $29.750M Estimate Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly earnings of $0.03 per share which beat the analyst consensus estimate of $(0.29) by 110.34 percent. This is a 109.09 percent increase over…
globenewswire.com Monte Rosa Therapeutics Announces Third Quarter 2026 Financial Results and Business Updates Positive GFORCE-1 Phase 1 results showed MRT-8102 reduced key pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) to levels comparable to healthy volunteers across all three dose…
benzinga.com Monte Rosa To Receive $37.5M Milestone Payment From Novartis Following Initiation Of Second Phase 2 Trial Of MRT-6160 In Psoriatic Arthritis Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that its collaborator Novartis has…
benzinga.com Monte Rosa Says Its Collaborator Novartis Initiates Second Phase 2 Clinical Study For VAV1-Directed MGD MRT-6160 In People Living With Active Moderate To Severe Psoriatic Arthritis Phase 2 study to be conducted in participants with active moderate to severe psoriatic arthritisNovartis conducting study under global exclusive development and commercialization license agreement…
benzinga.com HC Wainwright & Co. Reiterates Buy on Monte Rosa Therapeutics, Maintains $25 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and maintains $25 price target.
benzinga.com Monte Rosa Therapeutics Investigational Drug Shows Potential for Cardiovascular Disease Monte Rosa Therapeutics reports positive Phase 1 trial data for MRT-8102 and outlines upcoming Phase 2 studies in inflammatory diseases.
benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers DataMEDS AI (NASDAQ:MEDS) stock moved upwards by 39.4% to $4.42 during Thursday's pre-market session. The company's market cap stands at $10.1 million. Stablecoin Development (AMEX:SDEV)…- benzinga.com Monte Rosa Reports Data From GFORCE-1, Phase 1 Study Evaluating MRT-8102, NEK7-Directed MGD Being Developed For Treatment Of Inflammatory Conditions Driven By NEK7/NLRP3 Pathway In obese subjects at elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1-driven inflammatory diseases,…
benzinga.com GLUE Stock Soars Over 20% Pre-Market: What's Driving the Surge? Monte Rosa Therapeutics shares surged 20.03% premarket as investors awaited clinical data from its experimental heart-risk drug.
benzinga.com HC Wainwright & Co. Initiates Coverage On Monte Rosa Therapeutics with Buy Rating, Announces Price Target of $25 HC Wainwright & Co. analyst Mitchell S. Kapoor initiates coverage on Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy rating and announces Price Target of $25.
benzinga.com Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket Vicor shares surged 12% after raising Q3 growth guidance above 30%; Roze AI led gainers, while Corteva plunged 57% premarket.
benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's after-market session. The company's market cap stands at $1.0 billion. Filana Therapeutics (NASDAQ:FLNA)…- benzinga.com Wedbush Reiterates Outperform on Monte Rosa Therapeutics, Maintains $27 Price Target Wedbush analyst Robert Driscoll reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform and maintains $27 price target.
benzinga.com Guggenheim Reiterates Buy on Monte Rosa Therapeutics, Maintains $28 Price Target Guggenheim analyst Michael Schmidt reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and maintains $28 price target.
benzinga.com Monte Rosa Therapeutics Says First Patient Dosed In Modefire-1, Phase 2 Study Evaluating MRT-2359 In Combination With Apalutamide In Patients With mCRPC With AR Mutations Study will evaluate PSA and RECIST response, duration of response, radiographic progression-free survival (rPFS), and safetyUpdated data from the initial Phase 1/2 study of MRT-2359 plus enzalutamide…
benzinga.com JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27 JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $31 to $27.- benzinga.com Guggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $28 Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and lowers the price target from $35 to $28.
- benzinga.com Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $27 Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $29 to $27.
- benzinga.com Monte Rosa Therapeutics Q2 EPS $(0.43) Misses $(0.38) Estimate, Sales $8.968M Beat $5.524M Estimate Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.38) by 13.16 percent. This is a 186.67 percent decrease over…
- benzinga.com Wedbush Maintains Outperform on Monte Rosa Therapeutics, Lowers Price Target to $27 Wedbush analyst Robert Driscoll maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Outperform and lowers the price target from $37 to $27.
benzinga.com 12 Health Care Stocks Moving In Friday's Pre-Market Session Gainers Replimune Group (NASDAQ:REPL) shares increased by 134.6% to $12.69 during Friday's pre-market session. Moleculin Biotech (NASDAQ:MBRX) shares increased by 17.64% to $1.2. The market value of…- benzinga.com Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $35 Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and raises the price target from $30 to $35.
- benzinga.com JP Morgan Maintains Overweight on Monte Rosa Therapeutics, Raises Price Target to $31 JP Morgan analyst Brian Cheng maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and raises the price target from $30 to $31.
- benzinga.com Monte Rosa Therapeutics Q1 EPS $(0.45) Misses $(0.37) Estimate, Sales $4.210M Miss $10.883M Estimate Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.45) per share which missed the analyst consensus estimate of $(0.37) by 21.62 percent. This is a 178.95 percent decrease over…
benzinga.com 10 Health Care Stocks Whale Activity In Today's Session 
benzinga.com Monte Rosa To Present Preclinical Data Highlighting Potential Of CCNE1-Directed MGD, MRT-55811, To Treat CCNE1-Amplified Solid Tumors At AACR Annual Meeting 2026 CCNE1-directed molecular glue degrader (MGD) induced deep tumor regressions in CCNE1-amplified in vivo models of ovarian, breast, and gastric cancers CCNE1-directed MGD demonstrated superior…- benzinga.com Guggenheim Maintains Buy on Monte Rosa Therapeutics, Lowers Price Target to $30 Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and lowers the price target from $34 to $30.
- benzinga.com Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Lowers Price Target to $29 Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and lowers the price target from $30 to $29.
- benzinga.com Monte Rosa Therapeutics Q4 EPS $(0.55) Misses $(0.33) Estimate, Sales $2.781M Miss $15.506M Estimate Monte Rosa Therapeutics (NASDAQ:GLUE) reported quarterly losses of $(0.55) per share which missed the analyst consensus estimate of $(0.33) by 65.17 percent. This is a 339.13 percent decrease over…
- benzinga.com Monte Rosa Enters Into Supply Agreement With Johnson & Johnson To Evaluate MRT-2359 In Combination With ERLEADA For Treatment Of Patients With mCRPC With AR Mutations In Planned Phase 2 Study Expected To Initiate In Q3 Of 2026 MRT-2359 is an investigational, orally bioavailable, GSPT1-directed molecular glue degrader that has shown compelling clinical activity in combination with androgen receptor (AR) inhibition in…
- benzinga.com Monte Rosa Highlights Updated Phase 1/2 Data Showing 67% Overall RECIST Disease Control And Tumor Reductions In Heavily Pretreated mCRPC In mCRPC patients with androgen receptor (AR) mutations, treatment with MRT-2359 in combination with enzalutamide led to a 100% PSA response rate (5 of 5 patients) and a 100% disease control rate,…
- benzinga.com Piper Sandler Reiterates Overweight on Monte Rosa Therapeutics, Raises Price Target to $37 Piper Sandler analyst Edward Tenthoff reiterates Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and raises the price target from $27.5 to $37.
- benzinga.com Wells Fargo Maintains Overweight on Monte Rosa Therapeutics, Raises Price Target to $30 Wells Fargo analyst Derek Archila maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Overweight and raises the price target from $22 to $30.
- benzinga.com Guggenheim Maintains Buy on Monte Rosa Therapeutics, Raises Price Target to $34 Guggenheim analyst Michael Schmidt maintains Monte Rosa Therapeutics (NASDAQ:GLUE) with a Buy and raises the price target from $16 to $34.
- benzinga.com Monte Rosa Therapeutics Terminates ATM Prospectus After Selling 2.96M Shares For $24.2M In Net Proceeds Effective January 7, 2026, Monte Rosa Therapeutics, Inc. (the "Company") terminated the sales agreement prospectus (the "ATM Prospectus") filed with the Company's registration statement on Form S-3…
- benzinga.com Monte Rosa Therapeutics Commences Offering Of $200M Common Stock, Pre-Funded Warrants Monte Rosa Therapeutics, Inc. ("Monte Rosa") (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has…
benzinga.com Crude Oil Down 2%; ISM Services PMI Surges In December - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
benzinga.com Monte Rosa's Experimental Drug Slashes Inflammation Linked To Heart Disease Monte Rosa revealed positive interim Phase 1 data of MRT-8102. Data showed safety, tolerability, and reduction in inflammatory markers.
benzinga.com Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Higher On Wednesday - benzinga.com Market-Moving News for January 7th GLUE: 42% | Monte Rosa Therapeutics shares are trading higher after the company announced it will present interim clinical results from the ongoing Phase 1 study of NEK7-directed MGD MRT-8102. VTYX:…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- benzinga.com Monte Rosa Therapeutics' Interim Data From an Ongoing Phase 1 Trial of MRT-8102 Shows C-Reactive Protein Level Reductions in Cardiovascular and Cardiometabolic Diseases In subjects with elevated cardiovascular disease (CVD) risk, MRT-8102, a NEK7-directed molecular glue degrader in development for the treatment of NLRP3/IL-1/IL-6 driven inflammatory diseases,…
- benzinga.com Monte Rosa Therapeutics To Present Interim Clinical Results From The Ongoing Phase 1 Study Of The NEK7-Directed MGD MRT-8102 On Wednesday, January 7, at 8:00 a.m. ET Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that management will host a live…
benzinga.com Why Is Monte Rosa Stock Trading Higher Today? Monte Rosa reports interim Phase 1/2 data showing durable responses and manageable safety for MRT-2359 plus Pfizer's Xtandi in advanced prostate cancer patients.- benzinga.com Wells Fargo Upgrades Monte Rosa Therapeutics to Overweight, Raises Price Target to $22 Wells Fargo analyst Derek Archila upgrades Monte Rosa Therapeutics (NASDAQ:GLUE) from Equal-Weight to Overweight and raises the price target from $13 to $22.